Beta Bionics (NASDAQ:BBNX) Stock Price Up 8.2% – Time to Buy?

Beta Bionics, Inc. (NASDAQ:BBNX)’s share price rose 8.2% during mid-day trading on Thursday . The company traded as high as $13.25 and last traded at $13.4730. Approximately 81,004 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 1,131,098 shares. The stock had previously closed at $12.45.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on BBNX shares. Weiss Ratings cut shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Bank of America dropped their price objective on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research note on Monday, May 18th. The Goldman Sachs Group dropped their price objective on shares of Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Stifel Nicolaus dropped their price objective on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Finally, UBS Group raised shares of Beta Bionics to a “strong-buy” rating in a research note on Monday, February 9th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $19.70.

Beta Bionics Stock Performance

The stock’s 50 day moving average price is $10.93 and its two-hundred day moving average price is $17.19. The firm has a market capitalization of $618.94 million, a PE ratio of -9.20 and a beta of 3.40.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The business had revenue of $27.63 million during the quarter. Analysts expect that Beta Bionics, Inc. will post -2.19 earnings per share for the current year.

Insider Transactions at Beta Bionics

In other Beta Bionics news, insider Mark Hopman sold 5,329 shares of Beta Bionics stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total value of $67,198.69. Following the completion of the sale, the insider directly owned 130,887 shares of the company’s stock, valued at approximately $1,650,485.07. The trade was a 3.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mike Mensinger sold 4,378 shares of Beta Bionics stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total transaction of $55,206.58. Following the completion of the sale, the insider directly owned 184,415 shares of the company’s stock, valued at $2,325,473.15. The trade was a 2.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 27,687 shares of company stock worth $343,586 in the last three months. 5.30% of the stock is currently owned by company insiders.

Institutional Trading of Beta Bionics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Summit Securities Group LLC purchased a new stake in Beta Bionics in the 4th quarter worth approximately $52,000. Caitong International Asset Management Co. Ltd grew its stake in Beta Bionics by 1,075.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after acquiring an additional 1,818 shares during the period. EverSource Wealth Advisors LLC grew its stake in Beta Bionics by 203.6% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after acquiring an additional 1,594 shares during the period. Strs Ohio purchased a new stake in Beta Bionics in the 1st quarter worth approximately $29,000. Finally, Ameritas Investment Partners Inc. grew its stake in Beta Bionics by 139.1% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock worth $64,000 after acquiring an additional 1,863 shares during the period.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.